In a report released yesterday, Ryan Langston from TD Cowen maintained a Buy rating on Privia Health Group, with a price target of $30.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ryan Langston’s rating is based on the impressive financial performance and strategic growth initiatives of Privia Health Group. The company reported a significant 36% increase in EBITDA for the third quarter of 2025, surpassing market expectations, primarily due to strong performance in Medicare Advantage capitation. Additionally, Privia Health has consistently raised its full-year EBITDA guidance, now set at $120 million, reflecting its robust operational momentum.
Furthermore, the company’s strategic acquisition of the $100 million EVH ACO is expected to expand its market presence and contribute positively to future earnings. Privia Health’s strong balance sheet, with $410 million in cash and no debt, provides a solid foundation for continued growth. The management’s commitment to maintaining a 20% annual EBITDA growth and its ability to convert a significant portion of EBITDA to free cash flow further supports the positive outlook. These factors collectively justify the Buy rating assigned by Ryan Langston.
In another report released yesterday, Needham also reiterated a Buy rating on the stock with a $30.00 price target.